Bristol Myers Squibb Reports Preliminary Positive Alzheimer’s Psychosis Data
Bristol Myers Squibb said preliminary data from two late-stage studies showed its experimental treatment improved psychosis symptoms associated with Alzheimer’s disease.
Bristol Myers Squibb said preliminary data from two late-stage studies showed its experimental treatment improved psychosis symptoms associated with Alzheimer’s disease.